# Sigilon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sigilon-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.sigilon.com
- Total disclosed funding: $80M
- Latest round: Series B (Mar 17, 2020)
- Investors on record: 5

## About

Sigilon Therapeutics, Inc. is a biotechnology company based in the US, focused on developing innovative therapies utilizing its proprietary product platform to address unmet medical needs.Founded in 2015 in Cambridge, US, Sigilon Therapeutics, Inc. specializes in cell therapy development. The company had a significant pivot when Eli Lilly and Company acquired it in June 2023 for USD 309.60 mn, following a successful IPO in December 2020 that raised USD 126 mn. The co-founders, Daniel Anderson and Omid Veiseh, have backgrounds in biotechnology, contributing to the company's strategic direction and innovations. The current CEO is Rogério Vivaldi.Sigilon Therapeutics, Inc. develops advanced cell therapies designed to treat chronic diseases and genetic disorders. Their proprietary platform enables the creation of cell-based therapies that can provide sustained delivery of therapeutic proteins, addressing various unmet medical needs in the healthcare sector.In 2022, Sigilon Therapeutics, Inc. generated revenue of USD 12.94 mn, with an EBITDA of USD -42.39 mn for the same year, reflecting the company's focus on research and development.Following its acquisition in June 2023 by Eli Lilly and Company, Sigilon Therapeutics, Inc. plans to utilize the raised funds to expand its cell therapy development initiatives. The company aims to introduce new products targeting chronic and genetic diseases, with specific plans to enter additional markets in North America and Europe by the end of 2024. This strategic focus is part of their broader goal to enhance therapeutic options available to patients.

## Funding rounds

- Series B, Mar 17, 2020, $80M — Flagship Pioneering, CPP Investment Board, BlackRock, Eli Lilly & Company, Longevity Vision Holding

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series B
- CPP Investment Board — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Eli Lilly & Company — Series B
- Longevity Vision Holding (https://capitalatlas.ai/funds/longevity-vision-holding) — Series B